Welcome, Guest |
TOPIC:
Harvoni vs Daklinza 7 years 2 months ago #23764
Recently we saw SVR rates of 91-92% reported for Harvoni in a big (4200+) group of patients treated by the US VA. fixhepc.com/forum/experts-corner/1316-ha...va-study-n-4365.html At CROI 2017 further results from the German GECCO study were reported, and if you have a look at figure 3 there is a strong suggestion that Sofosbuvir + Daclatasvir is a better choice for GT1 than Harvoni. We have seen similar results with generics. www.croiconference.org/sites/default/files/posters-2016/584.pdf YMMV | |
Harvoni vs Daklinza 7 years 1 month ago #23883
| I support this by my own experience as a previous GT1a that extended with Sofosbuvir/Daclatasvir . GT1a Dec14 F2/8.7 VL 900000-2.5M Jan16 Hepcivir-L MonkMed/Redemption Baseline: VL 913575 Alt 76 Platelets low Wk2 VL1157 Alt 23 DET Wk 8 VL 32 Alt19 'In the slow lane' June16 Fibro 5.7 F0/1 LIF 1.5 Wk 11 VL<12 Alt 13 Det/Unq Extending tx 12 wks Mylan Sofo/Dac MonkMed Wk 14 VL <12 Det/Unq Wk 16 VL UNDETECTED Wk 22 + 4 Wks Sunprevir FixHepC Wk 24 UNDETECTED Alt 13 Wk 12 post tx SVR12 Wk 26 SVR24 Thank-you Tim, Dr Debasis @ MonkMed & Dr Freeman @ Fix HepC The following user(s) said Thank You: jimmy42 |
Time to create page: 0.067 seconds